Statera Biopharma Inc. (NASDAQ:STAB) Stock Sees Bullish Action As Company Plans Acquire Statera’s TLR5 Agonist Platform To
Statera Biopharma Inc. (NASDAQ:STAB) was up 17% after entering a strategic agreement with Coeptis Therapeutics Inc. (OTCMKTS:COEP). Under the terms of the strategic agreement, Coeptis will purchase Statera’s toll-like receptor 5 (TLRs) agonists platform that includes entolimod. Trading Data On Wednesday, STAB stock surged 17.40% to $0.3410 with more than 72.93 million shares, compared to its average volume of 3.23 million shares. The stock moved within a range of $0.3350…